ARWR logo

Arrowhead Pharmaceuticals, Inc.

ARWR
Healthcare|Biotechnology|US
$58.16
+0.70 (+1.22%)
Tangible Book / Share
$3.21
Cash / Share
$11.17

Analyst Consensus

Buy22 analysts
Strong Buy
0
Buy
16
Hold
6
Sell
0
Strong Sell
0
Consensus Target
$101.56
Implied Upside
+74.6%
Low Target
$46.00
High Target
$126.00

Price Target Trend

Last Month
$109.00
1 target · +87% vs price
Last Quarter
$94.33
3 targets · +62% vs price
Last Year
$90.00
26 targets · +55% vs price
All Time
$72.64
39 targets · +25% vs price

Rating Trend

Dec 25
9 buy · 4 hold · 0 sell
Jan 26
9 buy · 4 hold · 0 sell
Feb 26
9 buy · 4 hold · 0 sell
Mar 26
9 buy · 3 hold · 0 sell
Apr 26
10 buy · 3 hold · 0 sell
May 26
11 buy · 2 hold · 0 sell
Jun 26
11 buy · 2 hold · 0 sell
Jul 26
12 buy · 2 hold · 0 sell
Aug 26
12 buy · 0 hold · 0 sell
Sep 26
13 buy · 1 hold · 0 sell
Oct 26
14 buy · 1 hold · 0 sell
Nov 26
14 buy · 1 hold · 0 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Oct 15, 2026UBSJoon Lee$109.00(+87%)$58.37TheFly
Sep 24, 2026Goldman SachsAndrea Newkirk$74.00(+11%)$66.96TheFly
Aug 31, 2026RBC CapitalLuca Issi$100.00(+21%)$82.32StreetInsider
Aug 6, 2026H.C. Wainwright$120.00(+40%)$85.61TheFly
Aug 5, 2026Stifel Nicolaus$104.00(+16%)$89.59TheFly
Jul 27, 2026H.C. Wainwright$115.00(+34%)$85.60TheFly
Jul 23, 2026Morgan Stanley$120.00(+36%)$88.38TheFly
Jul 23, 2026Piper SandlerEdward Tenthoff$126.00(+42%)$88.70TheFly
Jul 22, 2026Chardan CapitalKeay Nakae$115.00(+26%)$91.03TheFly
Jul 13, 2026Stifel NicolausJames Condulis$98.00(+32%)$74.11TheFly
May 13, 2026Bernstein$46.00(-42%)$79.04TheFly
May 8, 2026Chardan Capital$90.00(+15%)$77.95TheFly
Apr 21, 2026Morgan Stanley$100.00(+44%)$69.25TheFly
Feb 6, 2026Morgan Stanley$78.00(+17%)$66.64TheFly
Jan 27, 2026Robert W. Baird$81.00(+21%)$67.02StreetInsider
Jan 21, 2026H.C. Wainwright$100.00(+45%)$68.80TheFly
Jan 13, 2026UBS$110.00(+62%)$68.03StreetInsider
Jan 13, 2026Piper Sandler$110.00(+67%)$65.93TheFly
Jan 7, 2026Morgan Stanley$81.00(+14%)$70.81TheFly
Jan 7, 2026Chardan Capital$80.00(+13%)$70.81TheFly

Recent Rating Actions

FirmActionRatingDate
Chardan CapitalmaintainBuyOct 15, 2026
HC Wainwright & Co.maintainBuyOct 15, 2026
HC Wainwright & Co.maintainBuySep 1, 2026
RBC CapitalmaintainOutperformAug 31, 2026
Chardan CapitalmaintainBuyAug 31, 2026
HC Wainwright & Co.maintainBuyAug 6, 2026
B. Riley SecuritiesmaintainBuyJul 30, 2026
HC Wainwright & Co.maintainBuyJul 27, 2026
Piper SandlermaintainOverweightJul 23, 2026
Morgan StanleymaintainOverweightJul 23, 2026
Chardan CapitalmaintainBuyJul 22, 2026
JP MorganmaintainOverweightJul 17, 2026
HC Wainwright & Co.maintainBuyJul 1, 2026
Chardan CapitalmaintainBuyJun 30, 2026
Leerink PartnersmaintainMarket PerformJun 17, 2026
BernsteinmaintainMarket PerformMay 13, 2026
RBC CapitalmaintainOutperformMay 8, 2026
Morgan StanleyupgradeEqual Weight →OverweightApr 21, 2026
HC Wainwright & Co.maintainBuyMar 25, 2026
HC Wainwright & Co.maintainBuyFeb 10, 2026
B. Riley SecuritiesmaintainBuyJan 22, 2026
HC Wainwright & Co.maintainBuyJan 21, 2026
Piper SandlermaintainOverweightJan 13, 2026
Morgan StanleymaintainEqual WeightJan 7, 2026
Chardan CapitalmaintainBuyJan 7, 2026

Earnings History

Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Aug 4, 2026$-1.36$-1.28$75.3M$44.2M
May 7, 2026$-0.93$-1.09$73.7M$73.8M
Feb 5, 2026$0.22$0.60$264.0M$213.9M
Nov 25, 2025$-0.18$-0.11$256.5M$175.3M
Aug 7, 2025$-1.26$-0.94$27.8M$154.1M
May 12, 2025$2.75$-0.06$542.7M$116.3M
Feb 10, 2025$-1.39$-0.42$2.5M$19.1M
Nov 26, 2024$-1.38$-1.05$3.6M$55.1M

News

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at

Nov 7, 2026gurufocus.com
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included multiple studies of plozasiran in patients with familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), and interim results from a Phase 1/2a study of investigational ARO-DIMER-PA.

Nov 7, 2026businesswire.com
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and operational flexibility. The transaction retires Arrowhead's existing $400 million Sixth Street facility at a $68 million discount to the contractual minimum repayment amount and establishes a new $400 million Si.

Nov 4, 2026businesswire.com
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in Chicago. AHA 2026 Oral Presentations Date & Time: Saturday, November 7, 3:15 – 4:30 pm CT Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies Location: Learning Studio 2‚ Science and Technology Hall‚ South Hall Title: First-in-Human Trial of a Dual Functional RNAi Mo.

Nov 2, 2026businesswire.com
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) will have access to a newly licensed new treatment option available on the NHS to reduce extremely high levels of triglycerides (a type of fat) in their bloodstreams, if the response to diet and conventional triglyceride lowering therapies has been inadequate. REDEMPLO® (plozasi.

Oct 27, 2026businesswire.com
Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)

DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Risk and Volatility DBV Technologies has a beta

Oct 17, 2026defenseworld.net
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform

Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. ARWR plans to expand its CNS pipeline, initiating two new ARO-MAPT phase 2 trials and advancing four additional CNS candidates into the clinic by end of 2027. Recent milestones include strong Redemplo phase 3 data, positive ARO-DIMER-PA results, and FDA STAR program entry for Redemplo, supporting a robust long-term growth o…

Oct 15, 2026seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript

Oct 14, 2026seekingalpha.com
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Arrowhead Pharmaceuticals NASDAQ: ARWR presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central nervous system, alongside initial clinical results for its TRiM CNS delivery platform.

Oct 14, 2026marketbeat.com
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimer's disease and other tauopathies. These results represent the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier and achieve substantial target gene knockdown in the brain.

Oct 14, 2026businesswire.com
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead's upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated with repeated hospit…

Oct 7, 2026businesswire.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Breaks Below 200 Day Moving Average – Here’s Why

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $75.86 and traded as low as $62.22. Arrowhead Pharmaceuticals shares last traded at $62.35, with a volume of 2,249,374 shares traded. Analyst Upgrades and Downgrades Several research firms

Oct 6, 2026defenseworld.net
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and SHASTA-4 Phase III data show plozasiran achieves 79–81% median triglyceride reductions and favorable safety, with quarterly dosing and no liver fat or thrombocytopenia signals. Current financials reflect partner-driven revenue and a strategic buildout for sHTG; liquidity of ~$1.35B post-voucher suppor…

Oct 2, 2026seekingalpha.com
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead's central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he di…

Sep 29, 2026businesswire.com
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress

Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidates during the Morgan Stanley Global Healthcare Conference. Get ARWR alerts:Sign UpEarly Dimer Data Points to Dual-Target Approach Chief Executive Officer Chris Anzalone said the company's ARO-DIMER-PA candidate represented the first demonstration of knockdown of two genes with…

Sep 18, 2026marketbeat.com
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands

Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.

Sep 18, 2026marketbeat.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Sep 16, 2026seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sep 15, 2026seekingalpha.com
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's

Sep 15, 2026gurufocus.com
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC.

Sep 15, 2026businesswire.com